RORing against resistance

Why Oncternal’s ROR1 inhibitor could pair with BTK in chemo-resistant cancers


Oncternal Therapeutics Inc.’s ROR1 inhibitor could be combined with BTK inhibitors to increase response rates in chemotherapy-resistant or refractory hematologic cancers such as chronic lymphocytic leukemia and mantle cell lymphoma.

The Bruton’s tyrosine kinase (BTK) inhibitor Imbruvica ibrutinib from AbbVie Inc. and Johnson & Johnson is used to treat CLL and MCL after chemotherapy fails.

In clinical trials, only 17% of patients with previously treated MCL and no patients with previously treated CLL achieved a complete response to Imbruvica. “We hope that

Read the full 827 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE